Boehringer Ingelheim says it is on track to launch 25 new treatments in its human pharma division onto the market between now and 2030, fuelled by an R&D pipeline that it says is the best in its ...

Denmark's Zealand Pharma and German partner Boehringer Ingelheim have won the U.S. Food and Drug Administration's ...

Boehringer Ingelheim investiert mehr als 100 Mio. Euro in Bürogebäude Campus in Wien Meidling wird durch nachhaltiges Bauprojekt erweitert Mitte 2027 sollen weitere Arbeitsplätze für rund 990 Personen ...

Boehringer Ingelheim has entered a partnership with the NCD Alliance, a network dedicated to shaping a world in which everyone can live a healthy and productive life, free from the preventable ...

Arbeitsplätze für 990 Leute sollen ab Mitte 2027 bezugsfertig sein. Der Pharmakonzern Boehringer Ingelheim erweitert seinen Standort in Wien-Meidling um ein neues Bürogebäude für rund 990 ...

„Klares Bekenntnis zum Standort Wien“ „Dieses Bauprojekt ist für uns eine wichtige Investition in die Zukunft und gleichzeitig ein klares Bekenntnis zum Standort Wien“, sagte der Generaldirektor des ...

The Animal Antibacterial and Antibiotics Market is being driven by several key factors. Rising livestock production and ...

The clinical pipeline is constantly being further developed, and Boehringer Ingelheim expects new approvals also in oncology in the coming years. An important investment in the future is the new ...

(RTTNews) - Zealand Pharma A/S (ZEAL) reported that Boehringer Ingelheim announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation for survodutide (BI ...

Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts (MEDEX CRM)’, a scientific expert meeting, brought together healthcare ...

Amon forschte u.a. am Howard Hughes Medical Institute des Massachusetts Institute of Technology (MIT) und war mit Boehringer Ingelheim eng verbunden, erklärte der Leiter der weltweiten ...